Deals
Clovis Oncology Said to Weigh Sale of Biotech Company
This article is for subscribers only.
Clovis Oncology Inc., a developer of cancer treatments whose value has more than tripled this year, is exploring strategic options including a sale of the company, people with knowledge of the matter said.
Clovis is working with advisers including Credit Suisse AG to help it find a buyer, the people said, asking not to be identified as the information is private. The process is still in the early stages and the company is not yet in exclusive talks with any potential acquirer, one of the people said.